{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:40:41Z","timestamp":1790458841748,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jaad.2018.10.070","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T14:54:30Z","timestamp":1549810470000},"page":"735-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis"],"prefix":"10.1016","volume":"80","author":[{"given":"Sophie","family":"Leducq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Giraudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Maruani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jaad.2018.10.070_bib1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.jaad.2018.10.070_bib2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1399-3046.2011.01575.x","article-title":"Sirolimus in pediatric renal transplantation","volume":"15","author":"Kasap","year":"2011","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jaad.2018.10.070_bib3","first-page":"CD011272","article-title":"Rapamycin and rapalogs for tuberous sclerosis complex","volume":"7","author":"Sasongko","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.jaad.2018.10.070_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.070_bib5","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/pbc.23124","article-title":"Sirolimus for the treatment of complicated vascular anomalies in children","volume":"57","author":"Hammill","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.070_bib6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2340\/00015555-2300","article-title":"Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review","volume":"96","author":"Nadal","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2018.10.070_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","article-title":"Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis","volume":"146","author":"Haemel","year":"2010","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/jamadermatol.2016.3697","article-title":"Efficacy of topical sirolimus (rapamycin) for the treatment of microcystic lymphatic malformations","volume":"153","author":"Ivars","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.070_bib9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2133.2005.06438.x","article-title":"Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial","volume":"152","author":"Ormerod","year":"2005","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0378-6323.190844","article-title":"Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis","volume":"83","author":"Cinar","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.070_bib11","doi-asserted-by":"crossref","first-page":"e99071","DOI":"10.1371\/journal.pone.0099071","article-title":"Topical rapamycin as a treatment for fibrofolliculomas in Birt-Hogg-Dub\u00e9 syndrome: a double-blind placebo-controlled randomized split-face trial","volume":"9","author":"Gijezen","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/lsm.22548","article-title":"Treatment of port wine stains using pulsed dye laser, erbium YAG laser, and topical rapamycin (sirolimus)-a randomized controlled trial","volume":"49","author":"Greveling","year":"2017","journal-title":"Lasers Surg Med"},{"issue":"3","key":"10.1016\/j.jaad.2018.10.070_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs R D"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jaad.2014.10.011","article-title":"Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial","volume":"72","author":"Marqu\u00e9s","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","article-title":"Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial","volume":"153","author":"Wataya-Kaneda","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.10.070_bib16","first-page":"A143","article-title":"Novel treatment option of sirolimus ointment for facial angiofibromas in individuals with tuberous sclerosis complex (TSC)","volume":"101","author":"Amin","year":"2016","journal-title":"Arch Dis Child"},{"issue":"9","key":"10.1016\/j.jaad.2018.10.070_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/lsm.22189","article-title":"Targeted topical and combination laser surgery for the treatment of angiofibromas","volume":"45","author":"Bae-Harboe","year":"2013","journal-title":"Lasers Surg Med"},{"issue":"5","key":"10.1016\/j.jaad.2018.10.070_bib18","first-page":"323","article-title":"Topicale rapamycine voor de behandeling van faciale angio bromen bij tubereuzesclerosecomplex","volume":"24","author":"Bloemen-boot","year":"2014","journal-title":"Ned Tijdschr Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2018.10.070_bib19","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/archdermatol.2011.254","article-title":"Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol","volume":"147","author":"DeKlotz","year":"2011","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pediatrneurol.2014.02.016","article-title":"Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report","volume":"51","author":"Dill","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13555-017-0174-5","article-title":"Topical rapamycin for facial angiofibromas in a child with tuberous sclerosis complex (TSC): a case report and long-term follow-up","volume":"7","author":"Ebrahimi-Fakhari","year":"2017","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-0960.2011.00837.x","article-title":"Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients","volume":"53","author":"Foster","year":"2012","journal-title":"Australas J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/09546634.2010.489598","article-title":"Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin","volume":"23","author":"Kaufman McNamara","year":"2012","journal-title":"J Dermatol Treat"},{"issue":"8","key":"10.1016\/j.jaad.2018.10.070_bib24","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ad.2013.09.013","article-title":"Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis","volume":"105","author":"Kn\u00f6pfel","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.070_bib25","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1365-2133.2011.10476.x","article-title":"Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis","volume":"165","author":"Mutizwa","year":"2011","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000357033","article-title":"Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy","volume":"228","author":"Park","year":"2014","journal-title":"Dermatol Basel Switz"},{"issue":"3","key":"10.1016\/j.jaad.2018.10.070_bib27","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/pde.12551","article-title":"Successful topical rapamycin treatment for facial angiofibromata in two children","volume":"32","author":"Pynn","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.070_bib28","doi-asserted-by":"crossref","first-page":"AB182","DOI":"10.1016\/j.jaad.2012.12.752","article-title":"Topical rapamycin in facial angiofibromas: assessment of clinical improvement and patient satisfaction in a series of 4 cases","volume":"68","author":"Rodrigo-Nicolas","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2018.10.070_bib29","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1468-3083.2011.04212.x","article-title":"Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis \u2013 associated facial angiofibroma","volume":"26","author":"Salido","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2018.10.070_bib30","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bjd.12567","article-title":"First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex","volume":"169","author":"Tanaka","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib31","first-page":"15","article-title":"Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response","volume":"18","author":"Truchuelo","year":"2012","journal-title":"Dermatol Online J"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ajd.12125","article-title":"Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions","volume":"55","author":"Tu","year":"2014","journal-title":"Australas J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.070_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ad.2011.02.019","article-title":"Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis","volume":"103","author":"Valer\u00f3n-Almaz\u00e1n","year":"2012","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.070_bib34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/0019-5154.152516","article-title":"Facial angiofibromas of tuberous sclerosis treated with topical sirolimus in an Indian patient","volume":"60","author":"Vasani","year":"2015","journal-title":"Indian J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/0019-5154.174087","article-title":"Use of topical rapamycin in facial angiofibromas in Indian skin type","volume":"61","author":"Viswanath","year":"2016","journal-title":"Indian J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.10.070_bib36","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1365-2133.2011.10471.x","article-title":"A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity","volume":"165","author":"Wataya-Kaneda","year":"2011","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2018.10.070_bib37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/0883073813488664","article-title":"A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex","volume":"28","author":"Wheless","year":"2013","journal-title":"J Child Neurol"},{"issue":"8","key":"10.1016\/j.jaad.2018.10.070_bib38","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/ced.12398","article-title":"Facial Angiofibroma Severity Index (FASI): reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma","volume":"39","author":"Salido-Vallejo","year":"2014","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2018.10.070_bib39","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jamadermatol.2014.4298","article-title":"Clinical and histologic analysis of the efficacy of topical rapamycin therapy against hypomelanotic macules in tuberous sclerosis complex","volume":"151","author":"Wataya-Kaneda","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/archderm.148.1.138","article-title":"A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex","volume":"148","author":"Wataya-Kaneda","year":"2012","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2018.10.070_bib41","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jamadermatol.2014.87","article-title":"Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin","volume":"150","author":"Muzic","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.070_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12458","article-title":"Use of topical sirolimus in the management of multiple familial trichoepitheliomas","volume":"30","author":"Tu","year":"2017","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjd.12315","article-title":"Familial multiple discoid fibromas: unique histological features and therapeutic response to topical rapamycin","volume":"169","author":"Wee","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.10.070_bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/dth.12182","article-title":"Classic Kaposi's sarcoma treated with topical rapamycin","volume":"28","author":"D\u00edaz-Ley","year":"2015","journal-title":"Dermatol Ther"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2018.10.070_bib45","first-page":"30","article-title":"Topical sirolimus: a novel treatment for chronic erosive plantar lichen planus","volume":"167","author":"Munidasa","year":"2012","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2018.10.070_bib46","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/09546634.2017.1306018","article-title":"Prospective pilot study on combined use of pulsed dye laser and 1% topical rapamycin for treatment of nonfacial cutaneous capillary malformation","volume":"28","author":"Doh","year":"2017","journal-title":"J Dermatol Treat"},{"issue":"2","key":"10.1016\/j.jaad.2018.10.070_bib47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/lsm.22436","article-title":"Port wine stain treated with a combination of pulsed dye laser and topical rapamycin ointment","volume":"48","author":"Griffin","year":"2016","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.jaad.2018.10.070_bib48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front Mol Neurosci"},{"issue":"1\u20132","key":"10.1016\/j.jaad.2018.10.070_bib49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijpharm.2016.05.064","article-title":"Formulation and characterization of a 0.1% rapamycin cream for the treatment of tuberous sclerosis complex-related angiofibromas","volume":"509","author":"Bougu\u00e9on","year":"2016","journal-title":"Int J Pharm"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218329050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218329050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:48:25Z","timestamp":1759272505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218329050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0190962218329050"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.10.070","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.10.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}